[1]韩 曦a,党 群a,胡 盈a,等.重度子痫前期孕妇血清Endocan 表达水平及其对胎儿生长受限的预测价值[J].现代检验医学杂志,2022,37(06):110-113+170.[doi:10.3969/j.issn.1671-7414.2022.06.020]
　HAN Xia,DANG Quna,HU Yinga,et al.Study on the Expression of Endocan in Serum of Pregnant Women with Severe Preeclampsia and Its Correlation with Fetal Growth Restriction[J].Journal of Modern Laboratory Medicine,2022,37(06):110-113+170.[doi:10.3969/j.issn.1671-7414.2022.06.020]
点击复制

重度子痫前期孕妇血清Endocan 表达水平及其对胎儿生长受限的预测价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年06期
页码:
110-113+170
栏目:
论著
出版日期:
2022-11-15

文章信息/Info

Title:
Study on the Expression of Endocan in Serum of Pregnant Women with Severe Preeclampsia and Its Correlation with Fetal Growth Restriction
文章编号:
1671-7414(2022)06-011-05
作者:
韩 曦a; 党 群a; 胡 盈a; 张 矛a; 王亚琴a; 谢小娟b
(陕西省人民医院a. 产科；b. 省临检中心，西安 710068)
Author(s):
HAN Xia;  DANG Quna;  HU Yinga;  ZHANG Maoa;  WANG Ya-qina ;  XIE Xiao-juanb
(a. Department of Obstetrics; b. Shaanxi Center for Clinical Laboratories, Shaanxi Provincial People’s Hospital, Xi’an 710068, China)
关键词:
重度子痫前期; 内皮细胞特异性分子; 胎儿生长受限
分类号:
R714.245；R392.11
DOI:
10.3969/j.issn.1671-7414.2022.06.020
文献标志码:
A
摘要:
目的 探讨重度子痫前期患者血清内皮细胞特异性分子(Endocan)表达水平对胎儿生长受限(fetal growthrestriction, FGR)的预测价值。方法 选取2020 年6 月~2021 年12 月于陕西省人民医院分娩的90 例重度子痫前期并发胎儿生长受限(FGR)孕妇为实验组，160 例重度子痫前期未并发FGR 孕妇为对照组。收集两组患者的临床资料，采用酶联免疫吸附法测定血清Endocan 的表达。采用Logistic 回归分析重度子痫前期FGR 发病的独立危险因素；采用ROC曲线分析Endocan 对重度子痫前期FGR 的预测价值。结果 实验组血清Endocan 表达(449.18±166.68pg/ml)显著高于对照组(331.44±63.07pg/ml)，差异有统计学意义(t=7.99，P ＜ 0.05)；Logistic 多因素回归分析，血清Endocan、舒张压及24h 尿蛋白是子痫前期FGR 发病的独立危险因素，这3 个危险因素联合检测对预测重度子痫前期孕妇FGR 发病的价值最高，ROC 曲线下面积为0.828(95%CI: 0.773~0.884)。结论 血清Endocan 是重度子痫前期FGR 发病的独立危险因素，其联合舒张压及尿蛋白检测对预测重度子痫孕妇FGR 的发病有一定价值。
Abstract:
Objective To investigate the predictive value of serum Endocan expression level in severe preeclampsia for fetal growth restriction(FGR). Methods 90 pregnant women with severe preeclampsia and FGR who delivered in Shaanxi Provincial People’s Hospital from June 2020 to December 2021 were selected as the experimental group, and 160 pregnant women with simple severe preeclampsia without FGR in the same period were selected as the control group. The clinical data of two group patients were collected, and the expression of Endocan in serum was determined by enzyme-linked immunosorbent assay. Logistic regression model was used to analyze the independent risk factors of FGR in severe preeclampsia. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of Endocan on FGR in severe preeclampsia. Results The level expression of serum Endocan in experimental group (449.18±166.68 pg/ml) was significantly higher than that in control group (331.44±63.07pg/ml), and the difference between the groups was statistically significant (t=7.99, P<0.001). Multivariate logistic regression analysis showed that serum Endocan, diastolic blood pressure and 24h urine protein were independent risk factors for FGR in severe preeclampsia. The combinaiton detection of three risk factors has the highest predictive value for FGR in women with severe preeclampsia, and the area under the curve was 0.828 (95% CI: 0.773~0.884) . Conclusion Serum Endocan level is an independent risk factor of severe preeclampsia complicated with FGR, and its combined detection with diastolic blood pressure and urine protein has certain predictive value for the onset of FGR in severe preeclampsia.

参考文献/References:

[1] BALTA S, BALTA I, MIKHAILIDIS D P. Endocan:a new marker of endothelial function[J]. Current Opinion in Cardiology, 2021, 36(4): 462-468.
[2] CROSS S N, BUHIMSCHI I A, BUNIAK C D, et al. Endocan, a soluble marker of endothelial cell activation is a molecular marker of disease severity in women with preeclampsia[J]. Reprod Sci, 2022 , 29(8):2310-2321.
[3] 杨怡珂 , 漆洪波．美国妇产科医师学会 (ACOG)“妊娠期高血压和子痫前期指南 2019版”要点解读 (第一部分 )[J].中国实用妇科与产科杂志 , 2019, 35(8): 895-899.
YANG Yike, QI Hongbo.Interpretation of the main points of ACOG guidelines for gestational hypertension and preeclampsia(2019) [J].Chinese Journal of Practical Gynecology and Obstetrics, 2019, 35(8): 895-899.
[4] 陈瑞欣 , 漆洪波 , 刘兴会 .2021年美国妇产科医师协会胎儿生长受限指南解读 [J].实用妇产科杂志 , 2021, 37(12): 907-909. CHEN Ruixin, QI Hongbo, LIU Xinghui. Interpretation of the 2021 American College of Obstetricians and Gynecologists fetal growth restriction guidelines[J]． Journal of Practical Obstetrics and Gynecology, 2021, 37(12): 907-909.
[5] 薛伟 , 易福凌 , 王苗 , 等．孕妇血清亲环素 A和组织型转谷氨酰胺酶水平检测与子痫前期发生不良妊娠的相关性研究 [J].现代检验医学杂志 , 2021, 36(6): 78-82. XUE Wei,YI Fuling,WANG Miao,et al. Correlation research between serum levels of cyclophilin A as well as tissue transglutaminase in pregnant women and adverse pregnancy in preeclampsia [J]. Journal of Modern Laboratory Medicine, 2021, 36(6): 78-82.
[6] 陈伟 .重度子痫前期发生胎儿生长受限的临床分析 [J].世界最新医学信息文摘 , 2021(66): 130-131. CHEN Wei. Clinical analysis of fetal growth restriction in severe preeclampsia [J].World Latest Medicine Information, 2021(66): 130-131.[7] ZHANG S M, ZUO L, ZHOU Q, et al. Expression and distribution of endocan in human tissues[J]. Biotechnic & Histochemistry, 2012, 87(3): 172-178.
[8] KUCUKBAS G N, KARA O, Y?CE D, et al. Maternal plasma endocan levels in intrauterine growth restriction[J]. The Journal of Maternal-Fetal & Neonatal Medicine, 2022, 35(7): 1295-1300.
[9] SZPERA-GOZDZIEWICZ A, KOSICKA K, GOZDZIEWICZ T, et al. Maternal serum endocan concentration in pregnancies complicated by intrauterine growth restriction[J]. Reproductive Sciences, 2019, 26(3): 370-376.
[10] CROSS S N, BUHIMSCHI I A, BUNIAK C D, et al. Endocan, a soluble marker of endothelial cell activation is a molecular marker of disease severity in women with preeclampsia[J]. Reproductive Sciences, 2022, 29(8): 2310-2321.
[11] 崔普芳 , 龚源 , 刘爱胜 , 等 .深圳地区妊娠期子痫前期孕妇血清中 IL-22, IL-17, IL-10,TGF-β水平表达及 IL-22基因 rs2227485T/C位点多态性分析 [J].现代检验医学杂志 , 2021, 36(6): 55-59． CUI Pufang, GONG Yuan, LIU Aisheng, et al. Expression of serum levels of IL-22, IL-17, IL-10 and TGF-βin pregnant women with preeclampsia during pregnancy and polymorphism analysis of IL-22 gene rs2227485 T/C locus in Shenzhen Area [J].Journal of Modern Laboratory Medicine, 2021, 36(6): 55-59.

相似文献/References:

[1]滕玲玲a,马广贞b,石 可a,等.重度子痫前期患者胎盘组织中CD44 mRNA和CD24 mRNA及蛋白表达水平的临床价值研究[J].现代检验医学杂志,2024,39(01):43.[doi:10.3969/j.issn.1671-7414.2024.01.008]
　TENG Linglinga,MA Guangzhenb,SHI Kea,et al.Clinical Value of CD44 mRNA and CD24 mRNA and Protein Expression Levels in Placental Tissue of Patients with Severe Preeclampsia[J].Journal of Modern Laboratory Medicine,2024,39(06):43.[doi:10.3969/j.issn.1671-7414.2024.01.008]

备注/Memo

备注/Memo:
基金项目：陕西省自然科学基础研究计划项目(2020-JQ937)，陕西省人民医院课题(2021BJ-11)。
作者简介： 韩曦(1982-)，女，博士，主治医师，主要从事产科危重症及并发症的临床救治，研究方向：产科危重症，E-mail：hanxi1934@163.com。
通讯作者：谢小娟(1981-)，女，博士，副主任技师，主要从事分子生物学检验，E-mail：xie198105@163.com。
更新日期/Last Update: 2022-11-15